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Abstract
Hepatocyte growth factor (HGF) is essential for injuryr epair.D espite high HGF levels in chronic ulcers, up-regulation of
HGF receptor in ulcer tissue and decreased biological activity of HGF in ulcer secretions haveb een observed. With as urface
plasmon resonance-based method, weassessed the binding of HGF to antibodies, receptors, and the basement membrane and
identiﬁed binding interactions that are indispensable for the biological activity of HGF.R ecombinant HGF (rHGF) lots were
tested for activity,s tructural integrity,a nd degradation, and the results were veriﬁed in an in vitro model of cell injury.
Biologically activer HGF,a sw ell as plasma from healthy volunteers, bound to heparan sulphate proteoglycan (HSPG) and to
anti-HGF antibodies. Decreased binding to HSPG was the ﬁrst event in rHGF degradation. This study established the
feasibilityof identifying patientswith chronic inﬂammation who need exogenous HGFand of using ligand-binding assessment
to evaluate rHGF lots for biological activity.
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Introduction
Hepatocyte growth factor (HGF)i sapotent growth
stimulator of mature epithelial cellst hat plays an
important role in regeneration and repaira fter injuries
(Matsumoto and Nakamura 1991).N atural HGF is a
heterodimeric protein of 96–110kDat hat consists of
one a chain (67kDa) and one b chain (35kDa; Godha
et al. 1988). Mesenchymalc ells produceH GF as a
single-chain precursor (Arakakie ta l. 1995),w hichi s
activated by the proteolytic function of HGF activator
(Miyazawa et al. 1993).T he HGF receptor, proto-
oncogene c-Met, is at ransmembrane protein
expressed on epithelial cells( Prat et al. 1991).I n
addition, at least two binding sites for HGFon rat liver
cell surfaces have been identiﬁed: ah igh-afﬁnity
c-Met/HGF receptor andaheparan sulphate proteo-
glycan (HSPG) binding site (Liu et al. 1992).
Basementm embranes support epithelial ande ndo-
thelialcells,preventthepassage ofproteins,andgenerate
histologicallyd istinctc ompartments in theb ody. These
membranesc ontain threem ajor components: collagen
IV,l aminin, andH SPG, allo fw hich arel ocalized to the
basall aminap ortion of basement membranes. HSPGi s
as ulphatedg lycoproteint hatb inds andf acilitates the
cytokine–receptori nteraction( Rescan et al.1 993) and
thec onversiono fp romitogen HGFt ot he two-chain
form (Liu et al. 1992) High levels of HGFh ave been
reported in bloodd uringa cute injuriess ucha si nfectious
diseases (Nayerietal.2002c).HGFisalsoproducedand
released locallyi naparacrinef ashion at thes ite of acute
injury( Nayeri et al. 2000, 2002b).
Surface plasmonr esonance (SPR) is an optical
technique that can simultaneously determine the
afﬁnityo faprotein for several ligands by using
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Johansen 1998; Nayerie ta l. 2005a). SPR enables
rapid analyte detection in real time without any
labelling of samplesa nd can be used for concentration
determination, kinetic studies, and epitope mapping.
The sensor surface of the SPR apparatus consists of a
carboxymethylated dextran matrix, whichi sahydro-
gel that provides as olution-like environment for the
biospeciﬁc interactions. The carboxyl groups in the
dextranm atrix enable the covalent couplingo fl igands
(proteins, receptors, DNA,e tc.) to the surface.U pon
testing several ligands that might bind HGF,w ef ound
at leastf ourl igands that were importantf or
distinguishing between different lots of rHGFo r
endogenous HGF (Nayeri et al. 2004, 2007). This
difference might haveb iological consequences such as
in the healing of ulcers( Nayerie ta l. 2002d).
ELISAisareliable,sensitive methodforthedetection
ofproteins insamples. Since1 998, we have determined
thec oncentration of HGFi nd ifferent recombinant
batcheso rb lood by usingacommercial ELISAk it
(R&D,M inneapolis,M N, USA),b ut we couldn ot
ascertaint he epitopea gainst whicht he monoclonal
antibody in thek it wasp roduced. However, we have
obtained reproducible resultsw itht he HGFE LISA kit
in severals tudies (Nayeri et al.2 000, 2002b,c).W hilst
studyingdifferentl otsofrHGFb yELISA,w eo bserved
thattheconcentrationofrHGFinreconstitutedsamples
correlated with thee xpectedc oncentration.H owever,
we didn ot ﬁndd ifferences betweenb iologicallya ctive
andi nactivel otsb yE LISA (Nayeri et al.2 004).T hus,
thecommercialELISA kitdeterminedthe totalamount
of HGFb ut provided no informationa bout theq uality
or activity.I narecent study, we showed that patients
with chronicu lcersh ad HGFw ithd ecreased activity
compared to patients with acuteu lcers (Nayeri et al.
2004). Thisobservationl ed us to investigatet he quality
of HGFb othe ndogenouslya nd in exogenousl otsi n
in vivo (Nayeri et al.2 007) and in vitro contexts.
In thep resent work,w ei ntroduce an SPR-based
method to evaluatet he qualitya nd biological activityo f
rHGF accordingt ot he relative binding response of the
cytokinet oanumber of biologically relevant ligands.
Ther esults obtained by this method correlated with high
sensitivitya nd speciﬁcity to ther esultso fabiological
assayi nt he CCL-53.1 cell line, whichr esponded
speciﬁcally to HGF( Nayeri et al. 2007).T he
predominantb inding response in biologically active
HGFw as identiﬁed.W ea lso show that systemic HGFi n
theb lood of patients with chronic legu lcersh ad
decreasedqualitycomparedwiththatofhealthycontrols.
Materials and methods
Patients
Venousb lood was gathered from 16 patients with
chronic leg ulcers( age range, 42–87y ears; median
age, 77 years; 4m en). Some of these patientsw ere
included in previouss tudies (Nayerie ta l. 2004,
2005b). The plasma was separated and keptf rozen at
2 708 Cp endinga nalysis.
Ulcer secretions
Ulcers ecretions were obtained from 10 patients with
chronic legu lcersa nd from 5p atientsw ith acute
ulcers.This materialwas used in previouss tudies from
our group (Nayerie ta l. 2004, 2005b).
Healthy controls
Plasmaw as obtained from 20 people( ager ange, 34–
83 years; median age, 55 years; 10 men) without any
signs of infection andw ith no history of chronic leg
ulcersa nd kept frozen.
Recombinant human hepatocyte growth factor
Recombinant hHGF wasagift from Professor
Nakamura, Osaka, Japan (2002). HGF was also
obtained commercially (10 lots from R&D Systems,
expressed in Sf 21 insect cells and in mouse myeloma
cell line NSO; 3l ots from Sigma Aldrich, St Louis,
MO,U SA; 1l ot from Santa Cruz Inc., SantaC ruz,
CA, USA; and 1l ot from GenWay Biotech Inc., San
Diego, CA, USA).
Buffyc oat
Abloodsamplewasobtainedbyvenouspuncturefroma
healthyblood donor,a5 9-year-oldman.Thebuffy coat
wasd ivided into twop arts.T he ﬁrstp ortion was
centrifuged at 3000 g for2 0min,a nd thes upernatant
wasc ollected.T he other part wasf rozena t 2 708 Cf or
1h to haemolyse theb lood cells,t hawed, and
centrifuged at 3000 g for2 0min,a nd thes upernatant
wascollected.Fromthesameindividual,abloodsample
wasg atheredi natube (VENOJECT
w silicone-coated)
andcentrifugedat3000g for20mintocollecttheserum.
Amounts( ELISA) andb inding character( Biacore) of
HGFi nt he buffyc oatb eforea nd afterh aemolysisa s
well as in thes erum were determined.
Endogenous HGF
Venous blood from ah ealthy 55-year-old man was
gathered in steriles ilicone-coatedt ubes (VEN-
OJECT
w )a nd placed at room temperature for 1h.
The liquid on top of the coagulated blood was
gathered and addedt oK aighn’sm odiﬁcation of
Ham’sF -12K medium (ATCC) supplemented with
10% foetal bovine serum (Sigma-Aldrich, Stockholm,
Sweden) in an atmosphere of 5% CO2 and 95% air at
378 C. After 48h, the medium was centrifugeda t
F. Nayerie ta l. 1643000g for 20min, and the supernatant was collected
and kept frozen at 2 708 C.
Evaluation of biological activity of HGFi namodelo fc ell
injury
Theb iological activity of HGFi ns amples wast estedi n
aninvitro cellinjuryassayusingtransformedmouseskin
epithelial cells( CCL-53.1 cell line). Them ethodi s
describedinapreviouspublication (Nayerietal.2 007).
CCl-53.1 cellsw ereg rown in Kaighn’s modiﬁcationo f
Ham’sF -12K medium (ATCC) supplemented with
15%horseserumand2.5%foetalbovineserum(Sigma-
Aldrich)i na na tmosphereo f5 %C O 2 and9 5% aira t
378 C. Aftert he cellsr eached conﬂuence, they were
separatedw ithn on-enzymatic cell dissociation solution
(1 £ )( Sigma-Aldrich),s uspended in F-12K medium
with 15%h orse seruma nd 2.5% foetal bovine serum,
andi noculatedo na24-wellc ulture plate( Nunc Brand
Products,R oskilde, Denmark).C ells were cultured
undert he same conditions for2 4–48h untilt hey
reachedconﬂuence.Then,theconﬂuentmonolayerwas
scrapedw ithasterile steeld evice. Detached cellsw ere
washed with PBS, andf resh medium wasa dded to the
wells. Theareaofthe squarenotc overedbycells(mm
2 )
wasm easured by microscopy (Olympus)a nd docu-
mentedineachwell.HGFwasadded,andthecellswere
incubateda t3 7 8 Ci nahumidiﬁeda tmospherec ontain-
ing5%CO 2 .After24and48h,theareanotcoveredbya
monolayerw as measured againa nd documented.
Ligands
Biologically relevant ligands of HGF [monoclonal
anti-HGFa ntibody( unknown epitope), polyclonal
antibodies against different parts of HGF,a nd HGF
receptors] were obtained commercially (Table I) and
immobilised on Biacore CM5 chips.
SPR measurementsa nd ligand immobilisation procedures
SPR measurements were conducted at 760nm in a
fully automatic Biacore 2000 instrument (GE-Health-
care GmbH,U ppsala, Sweden) equippedw ith four
ﬂow cells. The ﬂow cell temperature was 258 Ci na ll
experiments. Thes amples urfacesw ere carboxy-
methylated dextranC M5 chips( GE-Healthcare
GmbH). Couplingo fl igands to the carboxylic acid
groups of the dextran hydrogel was carried out by
conventional carbodiimide chemistryu sing 200mM
N -ethyl- N 0 -(3-diethylaminopropyl)c arbodiimide
(EDC) and 50mM N -hydroxysuccinimide (NHS).
The activation time was 7min, followed by a7 -min
ligandi njection. Deactivation of the remaining active
esters wasp erformed by a7 -mini njection of
ethanolamine/hydrochloride at pH 8.5. Aﬂ ow rate of
5 m l/min was usedd uring immobilisation.
Thel igands (Table I) were dilutedi n1 0mMa cetate
bufferat ap Hb elow thep rotein’s isoelectricp oint,thus
enhancingt he electrostatici nteractionsb etween the
dextranm atrixa nd thel igands.T he contactt imew as
7min,w hich resulted in levels of immobilisation
between8 000a nd 30,000 response units( RU). After
deactivation, the surfaces were washed with ﬁve
subsequent 1-mini njectionso f5 mM glycineb uffer,
pH 2.0, with 1MNaCl (regenerationb uffer).O ne of
theﬂ ow cellsw as used to monitort he response duet o
interactiono fH GF with thec arboxymethylated
dextranm atrix. This ﬂowc ellw as treatedi nt he same
Table I. Ligandsu sed to investigate the binding response of HGF by SPR.
Immobilised
ligands in SPR
Source/product
number Code Goal of investigation
Monoclonal anti-HGF AB R&D Systems/RDS
MAB294
MN Determine amount of HGF
Recombinant HGF
receptor (c-met)/fc chimera
R&D Systems/358
MT
c-Met Analyze HGF binding to c-met
receptor
HS proteoglycan Sigma-Aldrich/H4777 HSPG Analyze HGF binding to HSPG
Polyclonal anti-HGF AB,
afﬁnity isolated
Sigma-Aldrich/HH0652 PK Determine amount of HGF
H-170 rabbit
polyclonal AB
Santa Cruz/sc-13087 H-170 Bind amino acids 1–170 of human HGFb
N-19 afﬁnity-puriﬁed goat
polyclonal AB
Santa Cruz/sc-1356N -19 Peptide mapping at the N-terminus of
human HGFb
N-17 afﬁnity-puriﬁed goat
polyclonal AB
Santa Cruz/sc-1357N -17 Peptide mapping at the N-terminus of
human HGFa
C-20 afﬁnity-puriﬁed goat
polyclonal AB
Santa Cruz/sc-1358C -20 Peptide mapping at the C-terminus of
human HGFa
H-145 rabbit polyclonal AB Santa Cruz/sc-7949H -145 Bind amino acids 32–176 of human HGFa
D-19 goat polyclonal IgG Santa Cruz/sc-34461 D19
Epitope mapping in an internal
region of human HGFb
All ligands were diluted (1:10 in 10mM acetate buffer, pH 4.5) prior to immobilisation. AB, antibody.
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butt he ligand immobilisation step waso mitted.
LyophilisedrHGFwasreconstitutedandanalysedat
different concentrations. Sodium chloride (9mg/ml,
B. Braun Medical AB, Bromma, Sweden), distilled
water( B. Braun MedicalA B),p hosphateb uffer
solution (pH 7.4, Apoteket AB, Umea ˚ ,S weden), and
HBS-EP (0.01MH EPES, pH 7.4, 0.15MN aCl,
3mME DTA, 0.005% surfactant P20) (GE-Health-
care GmbH)w ere used as dilutionb uffers.A1:1
mixture of 1M NaCl þ 10mM glycine,p H2 ,w as
used as ar egeneration buffer.
The blood samplesw ere diluted 1:20 in phosphate
buffer solution (pH 7.4, Apoteket AB). One injection
of 1:1 1M NaCl:10mM glycine,p H2 ,f ollowed by
one injection of borate 8.5 was used as ar egeneration
buffer for the blood samples. Legu lcer secretionswere
diluted 1:10 in phosphate buffer solution. To avoid
the effects of degrading enzymes, ap rotease inhibitor
(1–5%) [4-(2-aminoethyl) benzenesulphonyl ﬂuoride
(AEBSF), pepstatin A, E-64, bestatin, leupeptin, and
aprotinin (but no metal chelators); Sigma Aldrich]
that speciﬁcally inhibited serine, cysteine, and aspartic
proteases and aminopeptidasesw as added to the leg
ulcer secretion 7–10min prior to analysis. A1 :1
mixture of 1M NaCl þ 10mM glycine,p H2 ,w as
used as ar egeneration buffer.
The presented SPR data were extracted from the
Biacore sensorgrams after the injections were ﬁnished,
i.e. during the analyte dissociation phase. One Biacore
RU corresponds to as urface concentration of 1pg
protein per mm
2 (Stenberg et al. 1991).T he binding
of HGF to ligands was tested in fresh samplesa fter
reconstitution.T he effecto ft ime on the response was
tested by continuous analysis of binding over time on
the same chip and during the same run. The ligand
binding of HGF after incubation at room temperature
for 15hw as comparedw ith ligandb inding of af reeze-
thawed sample. In addition, the effect of intracellular
degrading enzymes on the binding of HGF to ligands
was tested in buffy coat before and after haemolysis.
Ap ositivecontrolwas includeda tt he beginning and at
the end of each runt oc onﬁrm the reliabilityo f
surfacesa fter several regeneration buffer injections.
ELISA
Ac ommercial ELISA kit (Quantikine Human HGF
96 tests, R&D Systems) was used to determine the
concentrationo fH GF in samples. Our grouph as used
this method since 1996, and the samep erson has
performed all tests to reduce the inter- and intra-assay
errors( Nayerie ta l. 2000, 2002b,c).
Statistics
Parametric( ANOVA)a sw ella sn on-parametric
(Mann–Whitney U test, Spearman’s regression test)
(Statistica) tests were used for statisticala nalyses, and
p , 0.05 was considereds tatistically signiﬁcant.
Results and discussion
The following procedures were repeated several times
with different lots and had reproducible outcomes.
Representative data are reported. The rHGF obtained
as ag iftf romP rofessorN akamura2 002w as
biologically active andw as SPRr esponsive( see
below) andw as used as positive control in some of
the experiments. However in the reportedr esults
HGF produced by leukocytes in ah ealthy volunteer
was used as ap ositive control.
rHGF
Responsive lots.T he rHGF lots that bound to all
ligands (Tables Ia nd II) with approximately the same
absolute RU values( termed “SPR responsive”) had a
motogenic effecto nC CL-53.1 cells in the in vitro
model of cell injury( . 95% sensitivity and speciﬁcity).
We showed previously (Nayerie ta l. 2007) that the
biologically active rHGF lots had motogenic effects on
CCL-53.1 cells; therefore, the SPR responsive lots
were consideredb iologically active (Table II). To
simplify the calculation, we used the ratio of the
binding responses to HSPG and to MN.B iological
activity was observedi nH GF lots in which the
HSPG/MN ratio was $ 0.3. However, the cut-off
ratio might be different in serum or plasma.
In SPRr esponsives amples,t here wasapositive and
signiﬁcant correlation betweenH GF amount ( m g/ml)
andt he SPRr esponse to epitopes ( r
2 ¼ 0.97,
p , 0.0001).A ss howni nT able III, theb inding signals
form onoclonala nti-HGF( MN)a nd polyclonal anti-
HGF(PK)decreasedwithdilutionoftherHGFsample.
As imilar ﬁnding waso btainedw henw ea nalysedH GF
in faecesf romp atientsw ith acutei nfectiousg astro-
enteritis(Nayerietal.2005a).Inthosepatients,theSPR
signalresponse correlateds igniﬁcantlywiththe amount
Table II. Analysis of SPR responsiver HGF.
MN (13065 RU) HSPG (13092 RU)
5 m g/ml 991 741
2.5m g/ml 644 421
1.25m g/ml 250 110
0.6m g/ml 150 49
0.3m g/ml 63 14.3
0.1m g/ml 25 4
HBS buffer 2 40
Freshly reconstituted rHGF was diluted to different concentrations
in HBS buffer, and the binding signal to twol igandswas reported by
SPR. This lot of rHGF was biologically activeo nC CL-53.1 cells.
There was as igniﬁcant positivec orrelation between the HGF
concentration ( m g/ml) and the binding signal to MN (SPR) in this
lot ( r ¼ 0.98%, r
2 ¼ 0.97%, p , 0.0001). The immobilisation
levels for ligands are giveni np arentheses.
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However, in anotherp atient groupw ithc hronic
inﬂammatoryb owel disease, theS PR signal response
didn ot correlate with ELISAr esults (article under
preparation).Theseresultsmightindicatethatapositive
correlationb etween ELISAa nd SPRi sadeterminant
forb iologically active HGFa nd that biologicallya ctive
HGFi sp roduced endogenously during acute
inﬂammation.
Binding of HGF to HSPG/dextran sulphate (DS)
proved to be important for the biological activity of
HGF.T he addition of DS or HSPG to the samples
reduced the binding (i.e.d ecreased the response) of
HGF to the ligands (Figure 1), aswellas decreased the
biological activity of HGF.T his observation is similar
to the results obtained from analysis of HGF in the
faeces of patientsw ith acutei nfectious gastroenteritis
(Nayerie ta l. 2005a), in which the binding signalt o
HGF ligands in SPR decreased signiﬁcantly after the
additiono fD St ot he samples. The decrease in
binding signalm ight implyt hat the dextran-binding
siteo fH GF overlaps with the antibody-binding
epitope,o rt hat dextran binding induces ac onfor-
mationalc hangei nt he HGF molecule.
In common with manyother growth factors( e.g. the
ﬁbroblastg rowth factor family and vascular endo-
thelial growth factor),H GF displays as trong afﬁnity
for heparin, and this proved to be au seful aid in its
puriﬁcation( Nakamura et al.1 986).H eparan
sulphate (HS) is widely expressed, in the formo f
variousp roteoglycan species,o nt he surfaces of most
cells andi ss ecreted directly into the extracellular
matrix (Nakamura et al. 1986).L yone ta l. (1994)
demonstrated by afﬁnity chromatography that HGF
interacted with HSPG under physiological conditions
of pH and ionic strength. This interaction appearedt o
be mediateds olely by the HS chains and was of
comparable afﬁnity to the interaction of HGF with
heparin. In addition, heparin competitively inhibited
the binding of HGF to HSPG. These results indicate
that the primaryH S-binding site, and perhaps also the
heparin-binding site, is presento nt he a -chain of HGF
(Gallagher 1989). The HGF-binding site is present
withint he iduronate- and sulphate-richd omains of
HS, and its structure has beenp artially elucidated
(Gallagher 1989). The interaction of HSPG with
HGF seems to be mediated primarily by the HS
chainsa nd not the protein core.
Figure 1s hows that theb inding of HGFt o
antibodies raised against the N-terminuso fH GFb
(N19),t he N-terminuso fH GFa (N17), amino acids
32–176 of HGFa (H145), and an internal region of
HGF b (D19) mightc orrelate with the dextran-
binding afﬁnity of HGF.T he present work does not
address the mechanismo ft he difference between
biologically active and inactive HGF with regard to the
binding afﬁnity to these epitopes. However, previous
studiesh aveh ighlighted the role of HGFb in the
biological activity of HGF.S tamos et al. (2004)
Table III. SPR response (RU) and biological activity of samples containing HGF.
Samples containing
HGF
c-met
(22113 RU)
MN
(19194 RU)
HSPG
(14899 RU)
PK
(20978 RU)
Nude area in mm after 24h
(reported as ratio of þ HGF
area/control well area)
5 m g/ml GJ1750312 65 2000 226 326 nd
4 m g/ml GJ1750312 01 1842 133 231 2.5/3.5
0.8m g/ml GJ175031 120 473 77 132 0.5/3.2
0.8m g/ml GJ175031 þ PK 3.1 2 1 2 1 2 33 .5/3.5
0.08m g/ml GJ1750319 25 15 93 .0/3.2
Endogenous HGF
from blood donor
209 172 218 221 0.9/3.3
RHGF QF031062
2–100ng/ml
12 6 2 5 2 33 .4/3.5
The immobilisation levels for ligands are given in parentheses. The same chip was used for all measurements. Biologically active endogenous
HGF was used as ap ositivec ontrol. The rHGF GJ175031 þ PK as well as the biologically inactiver HGF lot GJ1750031 (Nayeri et al.
2005b)atdifferentdilutionswereu sed as negativec ontrols.BecauserHGFGJ175031had bindingafﬁnityto all ofthe ligandsin the study,this
lot was termed “SPR responsive.”T he biological activity was determined by measurement of the nude area after addition of rHGF to injured
CCL-53.1 cells.T he motogen activity of biologically activeH GF causes migration of nearby cells towards the injured area and as ubsequent
decrease in nude area size (Nayeri et al. 2007). The biologically inactiver HGF QF031062 had no afﬁnity to the ligands at different
concentrationsa nd was therefore “SPR non-responsive.”
Figure 1. Effect of the addition of 10% DS (10mg/ml in MQ
water) to an rHGFlot (dilutedin PBS) on the SPR binding response
to different HGF ligands.
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reportedt he crystal structure of HGFb in complex
with the Sema and PSI domains of the c-Metr eceptor.
The c-Met Semad omain folds intoaseven-bladed b -
propeller in whicht he bottom faces of blades 2a nd 3
bind to theH GF b chain “active site region”.
Mutation of HGF residues in the area that corre-
spondsw ith the active site region in related serine
proteases signiﬁcantly impairedH GFb binding to c-
Met. Lokker et al. (1992)r eported that an HGF
variantw ith mutations at residues Y673 and V692,
whicha re located in the active site region of the HGF
b -chain,h ad binding afﬁnityf or c-Met in the context
of two-chain HGF but had signiﬁcantly impaired
biological activity.I naprevious study,w es howed that
after the binding of HGF from conditioned medium of
injuredk eratinocytest ot he c-Metr eceptor, the
afﬁnityo fH GF for the H-145 antibody (Table I)
decreased, which might indicate that the H-145
epitope is involved in HGF interaction with the c-Met
receptor (Nayerie ta l. 2006).F urther studies are
planned to investigate the underlying mechanisms for
these observations.
Non-responsive lots.T he lots of rHGF thats howed no
binding to any of the ligands or that bound MN
(Table I) but displayed much lower binding of HSPG
had no biological activity in the CCL-53.1 cell line
(Nayerie ta l. 2007) and were therefore regarded as
biologically inactive (Table II). Binding of HGF to
HSPG is important to facilitate the contact between
HGF and its receptor (Liu et al. 1992; Rescan et al.
1993).T his factor might explain why the rHGF lots
without afﬁnity for HSPG and DS were biologically
inactive.
Furthermore, the SPR non-responsivel ots did not
havet he same afﬁnitiest oa ntibodiesd eveloped
against HGF peptides (Table I). In some lots there
was ah igh afﬁnity of HGF for MN (with unknown
epitope,T able I) but am uchl ower afﬁnityt oo ther
surfaces( Figure 2). In some lots therew as no afﬁnity
to surfaces at all (Table III). As mentioned previously,
the SPR responsive,b iologically active lots showed a
binding response to all surfaces. We haven ot studied
the underlying mechanisms for such differences in
ligand-bindingp roﬁles between SPR responsivea nd
non-responsive lots. Further studies are planned to
analyse the molecularb asis of these differences.
Time-related changes in binding.B yr epeated analysis of
the binding responses ofdifferent HGF lots to surfaces
with time, we observed that the freshly reconstituted
rHGF lots from the same batch had as imilar binding
response to ligands. However, this binding response
decreased within minutes after reconstitution.T hus,
we analysed theb inding response of oneS PR
responsivea nd one SPR non-responsive lot to ligands
that might be importanti nd istinguishing the
biologically active lots. As shown in Figure 2, the
non-responsive rHGF lot had an initially high afﬁnity
to MN but muchl ower afﬁnity to D19 and HSPG.
However, the binding response to MN decreased
signiﬁcantly over time.O nt he other hand, in a
reconstituted SPRresponsiverHGF lot, thebinding of
HGFtoHSPGdecreasedastheﬁrststepintheprocess
of inactivation( Table IV). In another experiment, the
binding of carrier-free HGF was betterp reserveda fter
15ha tr oom temperature than after thawing as ample
within1 5h of freezing( 2 208 C) and reconstitution
(Table V).A lthough these arep reliminary
observations, the results might indicate that several
freeze-thaw cycles are notb eneﬁcial fort he biological
activity of rHGF lots.
Figure 2. Degradation of protein with time in the same run. The
diagram showsasimpliﬁed reporto ft he Biacore run( SPR signal;
RU) during 15hi nt he same chip.r HGF carrier-free R&D
(GJ1907011)w as reconstituted in 2mlP BS to ac oncentration of
2.5m g/ml. The ratio of the binding response to HSPG/MN in this
lot (rHGF carrier-free, R&D GJ1907011) was 14/1025 ¼ 0.01;
therefore, the lot was consideredb iologically inactive. Positivea nd
negativec ontrols werei ncluded in the study but are not shown.
Table IV.B inding afﬁnity of biologically activer HGF to MN and
HSPG during incubation at room temperature.
GJ1750031
MN
(22500 RU)
HSPG
(14500 RU)
rHGF,1 -h incubation 309 105
rHGF,2 4-h incubation3 72 10
rHGF þ DS, 1h 123 25
rHGF þ DS, 24h1 86 2 17
rHGF þ MN 1:20, 1h 23 33
rHGF þ MN, 24h 2 0.3 2 24
rHGF original þ HSPG 1:20 116 2 30
Lyophilized rHGF (5m g/ml) was reconstituted in PBS, pH 7.4, to
1ml( 5000ng/ml). 100m lw as added to one tube containing 900m l
PBS and to two other tubes containing 890m lP BS and 10m lD So r
MN to reach the dilution of 1:10 (500ng/ml). HSPG was added to
100m lu n-dilutedr HGF (5000ng/ml). The initial four sampleswere
analyzed in one Biacore run. Dilution and running of the four
samples took 1h.T he samples were kept at room temperature for
24ha nd then re-analysedi nt he same chip.T he immobilisation
levels (RU) are giveni np arentheses.
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we observedd ifferences between HGF lots in the
relativel igand-bindingr esponses that correlated
signiﬁcantly with their quality (Figure 3). Samples
containing bacteria or chemical preparations,w hich
are unsuitable for biological in vitro assays, could be
evaluated for HGF quality by SPR. In somer HGF
lots, the appropriate dilution of HGF to use in
experimentsc ould be determined by analyzing
different concentrationso fr HGF with the Biacore
instrument and by choosing the concentration that
gavet he most similar binding to all ligands (TableI II).
Buffy coat.r HGF lots were quiteu nstable in the SPR-
baseda nalysis of HGF. However, ourp revious studies
that analysedH GF in several patient groups( Nayeri
et al. 2000, 2002b,c) andt hat investigated the stability
of HGF in serum/plasma (Nayerie ta l. 2002a) showed
thatendogenousHGFisfairlystable.Theexactsource
of blood-borne HGF is unclear, but because HGF is
presenti nm any tissues, the tissues could contribute to
plasma HGFi na ne ndocrinem anner. Another
potential source of HGFi nt he blood is leukocytes,
which contain substantial amounts of immunoreactive
HGF (Wolf et al. 1991; Beppue ta l. 2001).
We questioned whether chemical stress on the
relatively stable endogenous HGFi nb lood might
inﬂuence itsb inding afﬁnityt ot he ligandst hatw ere
importanti nd istinguishingb iologically active HGF.
Theb uffy coat of peripheralb lood is readilya vailable
from bloodb anks andc ontainsavarietyo fw hite blood
cells(Wangetal.2006).Wholebloodwasgatheredfrom
ah ealthy volunteer, andt he buffyc oat wass eparated.
Theconcentration(ELISA)andbindingproﬁleofHGF
in thes upernatant of buffyc oat andi nt he serumo ft he
Table V. Binding of recombinant HGF (R&D carrier-free GJ174034, diluted in PBS) to ligands, showing degradation over time.
Samples containingH GF C-met (22377 RU) MN (19820 RU) HSPG (14337 RU)
2.5m g/ml freshly reconstituted 194 1260 95
After 34min þ PK (10m l) 1 2 1 2 19
2.5m g/ml after 15hr oom temperature 181 373 147
2.5m g/ml after 15h, 2 208 Ca nd thawed9 42 83 45
Negativec ontrol PBS 2 10 2 8 2 24
Positivec ontrol after 15h4 03 508 512
The results are obtained from Biacore runs performed on the same chip.T he immobilisation levels (RU) are mentioned in parentheses.
Figure 3. The histogram corresponding to aB iacore sensorgram from three lots of HGF.T he ﬁrst and second sensorgrams (1–2)( SPR non-
responsive) belong to HGF with no biological activity in the in vitro assay( CCL-53.1c ells). The last sensorgram (3) belongs to biologically
activeH GF,w hich bound to all ligands with approximately the same absolute RU values (SPR responsive). The pills are showing the
regenerationi njections.
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(Table V).T hisr esultm ight indicate that serumi sa
reliable source fora nalysiso fe ndogenousH GF.T he
pellet that containedt he cellsw as placed at 2 708 Ca nd
thenthawedtoinducehaemolysis.Theconcentrationof
HGFd eterminedb yE LISA in theh aemolyseds ample
wash ighert hant hat in then on-haemolysed buffyc oat,
butt he SPRr esponsef or alll igands in Biacoreh ad
decreasedb y , 50%( TableV I).T hisﬁ ndingm ight
indicate degradation of HGFb ye nzymes released after
leukocyte lysis, whichr esultedi nahigh amount of
biologically inactive HGF. Thus,S PR mightb eamore
accurate indicatoro fp rotein qualityt hanE LISA.
Patients
The HGF binding proﬁle in patients with chronic leg
ulcersw as examined.W eh ad observedp reviously that
these patientsh ad high amounts of endogenous HGF
in ulcer secretions but decreased biologicala ctivity of
HGF (from the sames ample)i nt he CCL-53.1 cell
line (Nayerie ta l. 2004,2 007).T here wasn o
signiﬁcant correlation between age or sexo fp atients
and healthy controls and the SPR response of HGF to
the ligands.T he binding response of HGF in plasma
and in the ulcer secretions of patients with chronic leg
ulcers differeds igniﬁcantly from that of healthy
controls (Table VII). Binding to ligands crucial for
the biological activity of HGF( e.g. HSPG, N17 and
N19) was decreased in the plasma from patients with
chronic ulcersc ompared with the plasma from healthy
controls. However, direct biological activity of HGF
was not observed upon adding whole blood, serum, or
plasma to CCL-53.1 cells.
The ratio of the binding response of HSPG/MN in
leg ulcer secretions correlated signiﬁcantly with the
biological activity of HGF (Figure 4). Therefore,
patientsw ith chronic leg ulcerse xhibited ac hangei n
the quality of HGF in the blood and decreased
biological activityo fH GF in ulcer secretions.
However, the mechanism behind the changed quality
of HGF in the blood of patients with chronic leg ulcers
is unclear. In some otherc hronici nﬂammatory
diseases such as lungﬁ brosis, increased levels but
decreasedb iologicala ctivityo fH GF have been
reported (Yamanouchi et al. 1998; Marchand-Adam
et al.2 006).F urther studies are plannedt oi nvestigate
the mechanisms in patientsw ithc hronic leg ulcers.
Table VI. Analysis of HGF in buffy coat of blood donor by SPR (RU) and ELISA (ng/ml).
HSPG c-Met N-17 D19 ELISA (dilution 1:10)
Buffy coat centrifuged 3000g for 20min, diluted 1:20 in PBS 35 247 272 335 3.7
Serum from same person, diluted
1:20 in PBS
38 317 336 330 2.3
Haemolysed buffy coat, frozen at
2 708 C, thawed, centrifuged at 3000g for 20min, diluted in 1:20 PBS
15 163 99 118 5.7
Statistical analysis of results could not be performed because there weret oo few observations.
Figure 4. Concentration (detected by ELISA), biological activity
(assessed in CCL-53.1 cells), and binding response to ligands
(analysed by SPR) of HGF in ulcer secretions of patients with acute
or chronic ulcers. The data on HGF concentration and biological
activity werer eported previously (Nayeri et al. 2004). The biological
activity was determined by measurement of the nude area after
addition of rHGF to injured CCL-53.1 cells.T he motogen activity
of biologically active HGF causes migration of nearby cells towards
the injured area and as ubsequent decrease in nude area size (Nayeri
et al. 2007). In the present study,t he ulcer secretions of the same
patients and the same material were analysed by SPR. There was a
signiﬁcant negativec orrelation ( r ¼ 0.70, r
2 ¼ 0.49, p ¼ 0.003)
between the SPR binding response to ligands (HSPG/MN ratio)
and the size of the nude area in injured CCL-53.1 cells.
Table VII. Statistical analysis of SPR ligand-binding response
(RU) of endogenous HGF in plasma of patients with chronic leg
ulcers ( n ¼ 16) compared with healthyc ontrols ( n ¼ 20).
Ligands Median chronic ulcers Median control p value
N-17 173 232 0.005*
HSPG 216 450 0.010*
HSPG 217 449 0.011*
N-19 220 446 0.014*
HSPG 222 444 0.017*
HSPG 224 442 0.021*
H-145 232 434 0.042*
H-170 245 421 0.10
C-20 251 415 0.15
PK 276 389 0.53
MN 279 386 0.60
c-Met 281 385 0.64
The ligands (Table I) werei mmobilisedo nf our Biacore chips, and
HSPG was included in all four chips. The p values ( * ¼ signiﬁcant)
indicatethatthe bindingafﬁnityofHGFto HSPG,N-17, N-19,and
H-145 differed signiﬁcantly between groups.
F. Nayerie ta l. 170Conclusion
SPR-based assessments of the binding proﬁle of HGF
to relevant ligands might rapidly ands ensitively
distinguish HGF variants with biological activity.
Appropriate for clinical studies, this methodm ight be
used for evaluation of the quality of endogenous HGF
and for recognition of patients who might beneﬁtf rom
exogenous HGF treatment.
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